fashion -WSS

fashion

author：entertainment 2025-10-03 00:40:43 - browse：5396

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Hospitals owned by private equity see complications spike 25%

entertainment

WSS

Virtual care provider acquires bankrupt Pear's prescription apps

Why health records don't always know when patients are dead

In Spain, a hospital brews its own CAR

SNAP should offer more nutrition education

Prior authorization will have to move faster under new Biden rule

Why health records don't always know when patients are dead

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Peter Hotez and the public health issue of online harassment

The surgeon had a dilemma only a Nazi medical text could resolve

Dobbs anniversary: the lost opportunity of abortion as health care

Grail spinoff by Illumina should end disastrous merger attempt

In Memoriam: Notable people who died in 2023

In Spain, a hospital brews its own CAR

Cancer drug shortages should be causing more outrage

How digital therapeutics firms are pivoting after Pear's bankruptcy

Duchenne breakthrough therapy leaves behind pioneering families

Parkinson’s finding may lead to tests and, someday, treatments

knowledge

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

CRISPR gene editing developments we’re watching in 2024

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Why health records don't always know when patients are dead

Francis Collins on trust in science and how Covid communications failed

David Ricks of Eli Lilly: best biopharma CEO of 2023

entertainment

entertainment

leisure time

explore